Bio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BIO
Bio-Rad Laboratories, Inc. (BIO) P/E ratio
As of 16 October 2026, Bio-Rad Laboratories, Inc. (BIO) trades at a P/E ratio of 42.5×. Over the past ten years it has ranged from 0.0× (December 2025) to 466× (August 2017); the current reading is higher than 79% of that period. That is above the Medical Devices industry median of 23.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 10.8× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 5.3× | 16.25% |
| FY2020 | 4.6× | (27.43%) |
| FY2019 | 6.3× | (67.07%) |
| FY2018 | 19.1× | (69.52%) |
| FY2017 | 62.5× | (67.17%) |
| FY2016 | 191× | 431.77% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 35.2× | (22.74%) |
| Mar 2026 | 45.6× | 320.85% |
| Dec 2025 | 10.8× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRKR Bruker Corporation compare | n/m |
| GKOS Glaukos Corporation compare | n/m |
| GMED Globus Medical, Inc. compare | 19.3× |
| PODD Insulet Corporation compare | 26.4× |
| SNN Smith & Nephew SNATS, Inc. compare | 35.4× |
| BIO Bio-Rad Laboratories, Inc. | 42.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 43.7× |
| HAE Haemonetics Corporation compare | 57.7× |
| PEN Penumbra, Inc. compare | 78.4× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)